Market Size of Inhaled Nitric Oxide Industry
| Study Period | 2021 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 4.60 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Inhaled Nitric Oxide Market Analysis
The inhaled nitric oxide market is expected to register a CAGR of nearly 4.6% during the forecast period.
The COVID-19 pandemic has impacted the global healthcare system, including the inhaled nitric oxide market. For instance, an article published in the journal IJP in May 2021 reported that in patients with COVID-19 with acute respiratory distress syndrome (ARDS), nitric oxide was linked to a slight increase in oxygenation. Initially, the market witnessed significant growth due to the rising number of COVID-19 cases, and the significant effect of liquid nitric oxide was linked to overcoming ARDS in COVID-19 patients by increasing arterial oxygenation. Now that COVID-19 cases have declined, it is anticipated that the demand for inhaled nitric oxide may stabilize.
The factors driving the growth of this market are the rising prevalence of respiratory and other associated diseases and ongoing research and development activities. The most prevalent element driving this market is rising cases of chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), acute respiratory disease syndrome (ARDS), and tuberculosis (TB), among others.
Asthma and COPD are considered the most common chronic disease worldwide and this has driven the need for inhaled nitric oxide. For instance, in August 2022, Lung India reported that the prevalence of Asthma among Indian children was around 18.2%. The same source suggests that there is a high prevalence of severe asthma in the emerging markets of the Middle East and Africa as well as Latin America, compared to the mid-range prevalence in North America and Europe.
Similarly, the rising cases of malaria reported globally are increasing the demand for inhaled nitric oxide. The inhaled nitric oxide reduces endothelial activation and parasite accumulation in the brain and enhances survival in cerebral malaria cases. In July 2022, WHO reported that in the year 2020, 241 million cases of malaria were estimated globally.
The ongoing research and development activities and clinical trials being conducted for the development of new drugs to prevent this disease are also expected to fuel the market growth. For instance, in February 2022, Glenmark launched a nitric oxide nasal spray (FabiSpray) in India for the treatment of adult patients with COVID-19 in partnership with SaNOtize.
While these factors are poised to give the market an impetus, strict application norms across various regions may slow down its growth over the studied period.
Inhaled Nitric Oxide Industry Segmentation
Nitric oxide is a gas that is inhaled, and it works by relaxing smooth muscles to dilate blood vessels, especially in the lungs. The gas is mainly used in a breathing machine (ventilator) to treat respiratory failure in premature babies and treat COPD and ARDS. The Inhaled Nitric Oxide Market is segmented by Product Type (Gas and Delivery Systems), Application (Neonatal Respiratory Treatment, Asthma and COPD, Acute Respiratory Distress Syndrome, Malaria Treatment, Tuberculosis Treatment, and Other Applications), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Product Type | |
| Gas | |
| Delivery Systems |
| By Application | |
| Neonatal Respiratory Treatment | |
| Asthma and COPD | |
| Acute Respiratory Distress Syndrome | |
| Malaria Treatment | |
| Tuberculosis Treatment | |
| Other Applications |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Inhaled Nitric Oxide Market Size Summary
The inhaled nitric oxide market is poised for steady growth, driven by the increasing prevalence of respiratory diseases such as asthma, COPD, and ARDS, alongside ongoing research and development activities. The market experienced an initial surge due to the COVID-19 pandemic, as inhaled nitric oxide was linked to improved oxygenation in patients with acute respiratory distress. However, as COVID-19 cases have declined, the market is expected to stabilize. The demand for inhaled nitric oxide is further bolstered by the rising cases of malaria, where it has been shown to enhance survival in cerebral malaria cases. The geriatric population's growth, particularly those over 65, is also contributing to the market's expansion, as asthma is prevalent in this age group. Despite these growth drivers, the market faces challenges from stringent application norms across various regions.
North America is anticipated to witness significant growth in the inhaled nitric oxide market, attributed to the high incidence of respiratory disorders, an aging population, and robust research and development activities. The presence of key market players and new product launches, such as Mallinckrodt's investigational inhaled nitric oxide delivery system, further support this growth. Initiatives by government and non-government organizations to raise awareness and educate patients about asthma are expected to increase the adoption of inhaled nitric oxide. The competitive landscape is marked by the presence of numerous global and regional companies, including Air Liquide Healthcare, Matheson Tri-Gas Inc., and Merck KGaA, among others. These companies are actively involved in advancing nitric oxide-based therapeutics, as evidenced by recent funding and development activities.
Inhaled Nitric Oxide Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Rising Prevalence of Respiratory and Other Associated Diseases
-
1.2.2 Ongoing Research and Development Activities
-
-
1.3 Market Restraints
-
1.3.1 Strict Application Norms across Various Regions
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD million)
-
2.1 By Product Type
-
2.1.1 Gas
-
2.1.2 Delivery Systems
-
-
2.2 By Application
-
2.2.1 Neonatal Respiratory Treatment
-
2.2.2 Asthma and COPD
-
2.2.3 Acute Respiratory Distress Syndrome
-
2.2.4 Malaria Treatment
-
2.2.5 Tuberculosis Treatment
-
2.2.6 Other Applications
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Inhaled Nitric Oxide Market Size FAQs
What is the current Inhaled Nitric Oxide Market size?
The Inhaled Nitric Oxide Market is projected to register a CAGR of 4.60% during the forecast period (2024-2029)
Who are the key players in Inhaled Nitric Oxide Market?
Bellerophan Therapeutics Inc., Mallinckrodt Pharmaceuticals (Novoteris), Merck KGaA, Linde Plc and BOC Healthcare are the major companies operating in the Inhaled Nitric Oxide Market.
